Oncoinvent appoints Dr. Zuzana Jiráková Trnková as Chief Medical Officer to lead Phase 3 preparations for Radspherin®
Dr. Jiráková Trnková brings more than 20 years of clinical development experience from Bayer, BioNTech, and Highlight Therapeutics, with expertise spanning global pivotal Phase III trials and alpha-emitting radiopharmaceuticals Oslo, Norway – 28 October 2026 – Oncoinvent ASA (OSE: ONCIN), a clinical-stage radiopharmaceutical company developing Radspherin®, a receptor-independent alpha-emitting therapy to eradicate cancer […]



